伴侣动物保健市场（按动物类型、产品类型、配方、通路和治疗领域）－2025-2032 年全球预测

预计到 2032 年，伴侣动物保健市场将成长至 1,518.2 亿美元，复合年增长率为 18.24%。

主要市场统计数据
基准年2024年	397.2亿美元
预计2025年	471.3亿美元
预测年份：2032年	1518.2亿美元
复合年增长率（%）	18.24%

引人注目的定位，涵盖伴侣动物健康领域日益增长的需求、不断变化的相关人员以及策略行动的优先领域

伴侣动物健康领域正经历一个加速转型的时代，这得益于饲主期望的改变、科技的进步和照护模式的持续演进。宠物主人越来越将动物视为重要的家庭成员，这推动了对先进诊断、专业营养和新型疗法的需求。同时，兽医诊所和通路合作伙伴正在调整其商业模式，重塑其服务和产品的交付方式，以适应远端医疗、家庭监控和全通路购买行为。

在此背景下，商业性相关人员必须将临床证据、消费者洞察和供应链韧性融入其策略决策中。投资重点正转向能够实现远端监控、提高诊断通量并提供可衡量临床结果的解决方案，这些方案能够引起临床医生和动物主人的共鸣。此外，监管审查和抗菌药物管理措施正在影响处方决策和产品开发路径。这些综合动态为寻求产品差异化并扩大兽医院网路和零售通路应用的创新者、製造商和分销商带来了挑战和机会。

展望未来，那些将科学严谨性与现实的商业化策略相结合，并预见到分销和定价压力变化的领导者将最有可能在这个快速成熟的领域中获得长期价值。

数位转型、个人化照护模式和供应链弹性如何重塑动物用药品的产品路径和竞争优势

伴侣动物健康生态系统正被几项趋同的变革重新定义，这些变革正在改变产品开发、临床实践和商业性参与。首先，数位化和互联医疗工具正从试点计划转变为医疗服务的核心要素，从而能够更早发现慢性疾病，并促进兽医和饲主之间更频繁的远距互动。这些工具正在催化新的资料流，以支持结果主导的价值提案和产品差异化。

其次，个人化预防方法日益流行，营养策略和标靶治疗可根据生命阶段、品种特征和合併症量身定制。消费者越来越愿意投资高端医疗，而临床医生也越来越寻求能够提升生活品质的实证干预措施，进一步强化了这个趋势。第三，供应链敏捷性和采购透明度已成为製造商和经销商应对不断变化的原料供应和不断变化的监管要求的策略要务。这些共同的转变使得研发、监理和商业团队之间跨职能协作的重要性日益凸显。

最后，随着新参与企业和老牌製造商将其产品组合扩展到诊断、营养、药品、疫苗等，竞争格局正在加剧。这种转变的累积效应正在创造一个市场，在这个市场中，临床信心、数位整合和通路成熟度将决定从利基应用到主流的转变。

评估累积关税压力将如何影响伴侣动物治疗、诊断和营养供应链中的采购、定价和准入

主要贸易伙伴预期将采取的关税措施可能会对进口原材料、成品或专用设备的伴侣动物保健公司产生累积影响。实际上，关税上调可能会增加製造商和经销商的到岸成本，从而挤压净利率，除非透过价格调整、资源配置或营运效率的提升来抵消。对于依赖跨境生产注射剂、诊断组件和活性药物成分的组织而言，关税的影响可能会增加采购风险，并鼓励近岸外包或供应商多元化。

除了直接的成本影响外，关税引发的变化还可能对供应链和消费行为间接影响。例如，由于企业优先考虑库存配置和营运成本保全，进口成本的增加可能导致产品发布延迟或促销强度减弱。因此，兽医和宠物饲主可能会发现自己无法获得某些进口诊断产品和专用营养配方，这促使他们用国产或学名药进行替代。监管合规和海关监管要求也可能延长前置作业时间，使需求计划更加复杂，并提高灵活库存策略的价值。

为了减轻累积关税的影响，鼓励相关人员评估基于情境的筹资策略，尽可能重新协商商业条款，并加速产品在地化进程。最终，製造基地的韧性和分销网络的敏捷性将决定企业如何有效地吸收关税压力，同时保持对诊所和消费者的服务水准。

将动物类型、产品结构、配方选择和渠道动态与临床应用和商业机会联繫起来的深入细分情报

要深入了解市场动态，需要了解多个细分领域的需求和采用模式，以指南产品设计和商业性执行。就动物种类而言，狗仍然专注于预防和慢性病护理创新，而猫则推动着谨慎的家庭治疗和专门营养补充剂的采用。就产品类型而言，包括影像、体外诊断和持续监测在内的诊断技术的进步使得更早的发现和更有针对性的治疗方案成为可能，而营养创新则强调针对生命週期需求和併发症管理的专门宠物食品配方和补充剂。药物涵盖了广泛的治疗方法，包括抗发炎药物、抗生素、内分泌疗法、止痛药和抗寄生虫药，每种药物都有各自的监管、定价和管理考虑。

剂型选择－注射剂、口服剂或外用剂－持续影响处方行为和病人顺从性。分销管道的动态变化进一步塑造了获取和购买模式：线上零售平台扩大了覆盖范围并提升了便利性，宠物专卖店在品牌发现方面保持了其重要地位，药店提供值得信赖的配药服务，而兽医诊所仍然是专家指导和照护现场产品使用的核心。在循环系统、牙科、皮肤病学、内分泌学、整形外科和寄生虫学等治疗领域，临床需求与创新管道相互交织，为有针对性的临床证据生成和商业策略创造了差异化的机会。

总的来说，这些细分强调了综合产品规划的重要性，该规划将配方、管道策略和治疗方法定位与临床工作流程和患者行为相结合，以推动采用并维持价值。

区域动态决定了美洲、欧洲、中东和非洲以及亚太市场的差异化商业化策略

临床实务、法规环境和消费者偏好的地区差异，形成了独特的区域动态，从而决定了市场参与企业和现有企业的策略重点。在美洲，成熟的兽医网络、较高的宠物拥有率以及消费者在预防性和高级护理方面的强劲支出，使得临床证据成为进入市场和实现差异化的关键手段。同时，供应链和报销结构影响着製造商在每个国家和地区市场中如何优先考虑分销和促销投资。

在欧洲、中东和非洲，监管协调工作与不同的市场成熟度并存，为区域客製化产品註册和差异化通路策略创造了机会。在部分地区，本地临床指南和抗菌药物管理计画可能会影响药物使用模式，促使製造商强调与管理相关的通讯和诊断辅助处方。在全部区域亚太地区，宠物拥有量的快速增长、都市区兽医基础设施的不断扩张以及可支配收入的不断增长，正在推动对优质营养、先进诊断和便捷治疗方案的需求。

综合起来，这些区域见解表明需要一个灵活的商业化框架，以平衡全球临床证据产生与特定区域的监管策略、通路伙伴关係以及适应消费行为和医疗保健提供模式差异的营销方法。

企业的策略重点与竞争措施：结合临床信誉、供应可靠性和通路成熟度，在动物用药品取胜

伴侣动物保健领域的竞争优势日益取决于能否将科学可信度与可扩展的商业性可行性结合。主要企业优先考虑融合诊断、治疗和营养解决方案的一体化产品组合，并以结果数据和临床医生教育计画为支持。策略联盟和选择性收购是扩展能力组合、获取独特技术以及加速进入相关治疗和分销领域的常用方法。

生产和监管事务中的卓越运作仍然至关重要，尤其对于需要严格品质系统的注射生技药品和高级诊断产品。投资于供应链视觉性和数位预测工具的组织将在库存优化和服务连续性方面获得优势。在商业方面，增强的数位行销、全通路销售支援和现场人员培训将有助于更有效地与兽医诊所和动物饲主互动。此外，更重视上市后证据和真实世界资料收集，可以强化临床价值提案，并支持与付款人和医疗保健组织进行采购谈判。

在这种竞争环境下，敏捷的中型企业可以透过专注于利基治疗领域或提供临床医生的差异化诊断平台，超越大型现有企业。相反，大型综​​合企​​业则利用其规模优势，提供全球供应的连续性和广泛的分销管道，与本地专家合作是实现本地化成长的有效途径。

高阶主管可以采取可行的策略行动，以增强证据产生、供应弹性和跨通路商业性差异化

产业领导者应制定多管齐下的行动计划，以确保临床信心、优化供应链并加速商业性应用。首先，优先开发可靠的临床和现实世界证据，证明患者疗效和饲主满意度显着改善。其次，重新设计筹资策略，透过供应商多元化、尽可能本地化以及库存灵活性来降低关税和物流风险，从而在市场波动期间保持服务水准。

同时，投资支援远端监控、远端医疗整合和全通路商务的数位基础设施，将解锁新的互动点并提高依从性。开发团队应针对线上零售商、专卖店、药局和诊所合作伙伴制定针对特定管道的价值提案，确保通讯的一致性和精简的履约选项。此外，将抗生素管理和法规合规性纳入产品策略，以体现临床责任，同时降低声誉和监管风险。最后，考虑建立伙伴关係和有针对性的併购，以获得利基技术和分销网络，并加快高价值创新产品的上市时间。

实施这些建议将有助于公司建立有弹性的、以证据主导的投资组合，以满足临床需求和不断变化的所有者期望，同时在日益复杂的全球环境中保护利润和准入。

结合从业者访谈、监管分析和情境规划的稳健混合方法研究途径，以检验商业性和临床见解

本调查方法采用混合方法，结合定性和定量证据收集、严格的次要研究和专家检验。主要研究内容包括与执业兽医、分销主管和产品开发负责人进行结构化访谈，以提供有关临床工作流程、应用障碍和通路经济性的观点。二次研究包括监管指南、临床文献和行业趋势分析，以将访谈结果具体化并识别系统性驱动因素。

分析方法包括跨细分综合法，以评估动物类型、产品类型、配方、分销管道和治疗重点如何相互作用，从而影响其应用和商业性成果。此外，还运用情境规划和敏感度分析来评估外部衝击（例如关税调整和供应链中断）的潜在影响。所有研究结果均由专家评审小组进行三角检验，以确保解释的严谨性和实际相关性。如果资料变异性或快速变化的监管条件可能影响短期适用性，本研究承认其局限性，并建议透过额外的基础研究和试点计画进行有针对性的检验。

这种多管齐下的方法确保见解植根于临床现实、具有商业性可行性并能适应不断变化的市场条件。

综合结论：临床创新、营运韧性与实证商业化是动物保健领域长期成功的支柱

摘要：伴侣动物保健产业正经历策略整合与创新时期，临床证据、供应链敏捷性和通路成熟度将决定成败。诊断技术的进步和数位化医疗能力正在改变护理节奏，使早期介入成为可能，并为那些能够展现出明显疗效的产品和服务创造机会。兼具配方便捷性和疗效的营养和药物产品组合，可望吸引日益增长的业主投资和临床医生的偏好。

关税相关压力和区域监管差异迫使企业采取积极的采购和打入市场策略，以维持市场准入和利润率。将强大的循证基础与适应性製造地和差异化商业模式相结合的企业，将能够更好地应对市场波动并确保永续成长。最终，通往长期成功的道路将取决于将临床创新转化为可扩展的、经实践检验的解决方案，以满足不断变化的所有者期望，同时维护管理和安全标准。

现在采取行动调整研发重点、营运能力和打入市场策略的相关人员将有可能在快速成熟的市场中创造可持续的竞争优势。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 越来越多采用远端医疗平台进行虚拟兽医咨询
• 消费者对特定品种和特定状况的宠物营养计划的需求不断增长
• 整合穿戴式健康追踪器，即时监测宠物的生命征象和活动水平
• 扩大宠物保险计划，涵盖预防保健和专业兽医护理
• 犬慢性疾病单株抗体治疗进展及商业化
• 兽医对基于 CBD 的宠物疼痛管理治疗方法的接受度和采用率不断上升
• 线上兽医药局和直接面向消费者的药品分销管道快速成长
• 开发数位行为健康工具以解决宠物的分离焦虑和压力
• 宠物食品对永续成分和环保包装的需求不断增长
• 加强「同一个健康」合作，将宠物疾病监测与人类健康数据整合

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 伴侣动物保健市场（依动物类型）

• 猫
• 狗
• 马

9. 伴侣动物保健市场（依产品类型）

• 诊断
  • 影像学
  • 体外诊断
  • 监控设备
• 营养
  • 特色宠物食品
  • 补充
• 製药
  • 抗发炎药物
  • 抗生素
  • 内分泌治疗
  • 疼痛管理
  • 杀寄生虫剂
• 疫苗

10. 伴侣动物保健市场（依配方）

• 注射
• 口服
• 外用药物

11. 伴侣动物保健市场（依通路）

• 网路零售
• 宠物专卖店
• 药局
• 兽医诊所

12. 伴侣动物保健市场（依治疗领域）

• 心血管系统
• 牙科
• 皮肤科
• 内分泌
• 整形外科
• 寄生虫学

13. 伴侣动物保健市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 伴侣动物保健市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

15. 伴侣动物保健市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Elanco Animal Health Incorporated
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • IDEXX Laboratories, Inc.
  • Ceva Sante Animale SA
  • Vetoquinol SA
  • Virbac SA
  • Dechra Pharmaceuticals PLC
  • Phibro Animal Health Corporation

The Companion Animal Health Market is projected to grow by USD 151.82 billion at a CAGR of 18.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 39.72 billion
Estimated Year [2025]	USD 47.13 billion
Forecast Year [2032]	USD 151.82 billion
CAGR (%)	18.24%

A compelling orientation to the companion animal health sector that frames rising demand drivers, stakeholder shifts, and priority areas for strategic action

The companion animal health landscape is undergoing an era of accelerated transformation driven by shifting owner expectations, technological advances, and evolving care models. Pet guardians increasingly view animals as integral family members, which has elevated demand for advanced diagnostics, specialized nutrition, and novel therapeutics. Concurrently, veterinary practices and channel partners are adapting operating models to accommodate telehealth, at-home monitoring, and omnichannel purchasing behaviors, reshaping how services and products are delivered.

Against this backdrop, commercial stakeholders must integrate clinical evidence, consumer insights, and supply chain resilience into strategic decision-making. Investment priorities are moving toward solutions that enable remote monitoring, improve diagnostic throughput, and deliver measurable clinical outcomes that resonate with both clinicians and owners. Moreover, regulatory scrutiny and antimicrobial stewardship initiatives are influencing formulary decisions and product development pathways. In combination, these dynamics create both challenges and opportunities for innovators, manufacturers, and distributors seeking to differentiate offerings and scale adoption across veterinary networks and retail channels.

Looking ahead, leaders who align scientific rigor with pragmatic commercialization strategies, and who anticipate shifting distribution and pricing pressures, will be best positioned to capture long-term value in this rapidly maturing sector.

How digital transformation, personalized care models, and supply chain resilience are reshaping product pathways and competitive advantage in animal health

The companion animal health ecosystem is being redefined by several convergent shifts that are transforming product development, clinical practice, and commercial engagement. First, digital and connected health tools are moving from pilot projects to core components of care delivery, enabling earlier detection of chronic conditions and more frequent remote interactions between veterinarians and owners. These tools are catalyzing new data streams that support outcome-driven value propositions and product differentiation.

Second, there is a pronounced move toward personalized and preventative approaches, with nutritional strategy and targeted therapeutics increasingly tailored to life stage, breed predispositions, and comorbidities. This trend is reinforced by growing consumer willingness to invest in premium care and by clinicians seeking evidence-based interventions that extend quality of life. Third, supply chain agility and sourcing transparency have become strategic imperatives as manufacturers and distributors respond to fluctuating input availability and evolving regulatory requirements. Together, these shifts elevate the importance of cross-functional collaboration among R&D, regulatory, and commercial teams.

Finally, the competitive landscape is intensifying as new entrants and incumbent manufacturers expand portfolios across diagnostics, nutrition, pharmaceuticals, and vaccines. The cumulative effect of these transformative shifts is a market where clinical credibility, digital integration, and channel sophistication determine who advances from niche adoption to mainstream acceptance.

Assessing how cumulative tariff pressures influence procurement, pricing, and access across companion animal therapeutics, diagnostics, and nutrition supply chains

Projected tariff actions originating from major trading partners can exert a cumulative influence on companion animal health companies that import raw materials, finished goods, or specialized equipment. In practical terms, higher duties increase landed costs for manufacturers and distributors, which can compress margins unless offset through pricing adjustments, re-sourcing, or operational efficiencies. For organizations that rely on cross-border production of injectables, diagnostics components, or pharmaceutical active ingredients, tariff exposure heightens procurement risk and may incentivize nearshoring or supplier diversification.

Beyond direct cost effects, tariff-induced shifts can create secondary impacts across supply chains and consumer behavior. For example, increased import costs may delay product launches or reduce promotional intensity as firms prioritize inventory allocation and working capital preservation. In turn, veterinarians and pet owners may experience constrained access to certain imported diagnostics or specialized nutritional formulations, prompting substitution toward locally produced alternatives or generics. Regulatory compliance and customs administration requirements can also extend lead times, making demand planning more complex and increasing the value of flexible inventory strategies.

To mitigate cumulative tariff impacts, stakeholders are advised to evaluate scenario-based sourcing strategies, renegotiate commercial terms where feasible, and accelerate product localization efforts. Ultimately, the resilience of manufacturing footprints and the agility of distribution networks will determine how effectively companies absorb tariff pressures while maintaining service levels for clinics and consumers.

Deep segmentation intelligence linking animal type, product architecture, formulation choices, and channel dynamics to clinical adoption and commercial opportunity

A granular view of market dynamics requires understanding demand and adoption patterns across multiple segmentation lenses that guide product design and commercial execution. When viewed through animal type, dogs remain a primary focus for preventive and chronic care innovations, while cats drive adoption in discreet, at-home treatments and specialized nutrition; equine markets prioritize performance, reproduction, and pain management solutions with distinct clinical pathways. Considering product type, diagnostic advances spanning imaging, in-vitro diagnostics, and continuous monitoring are enabling earlier detection and more precise treatment selection, whereas nutrition innovation emphasizes specialized pet food formulations and supplements that target lifecycle needs and comorbidity management. Pharmaceuticals encompass a range of modalities from anti-inflammatories and antibiotics to endocrine therapies, analgesics, and parasiticides, each with unique regulatory, pricing, and stewardship considerations.

Formulation choices-injectable, oral, and topical-continually influence prescribing behavior and owner adherence, with injectables favored for clinic-administered interventions, oral formulations supporting at-home chronic disease management, and topicals offering convenience for dermatological and parasitology indications. Distribution channel dynamics further shape access and purchasing patterns; online retail platforms are expanding reach and convenience, pet specialty stores maintain brand discovery roles, pharmacies offer trusted dispensing, and veterinary clinics remain central for professional guidance and point-of-care product use. Therapeutic area focus on cardiovascular, dental, dermatology, endocrine, orthopedic, and parasitology conditions highlights where clinical demand and innovation pipelines intersect, creating differentiated opportunities for targeted clinical evidence generation and tailored commercial strategies.

Taken together, these segmentation perspectives underscore the importance of integrated product planning that aligns formulation, channel strategy, and therapeutic positioning to clinical workflows and owner behaviors in order to accelerate adoption and sustain value.

Regional dynamics that dictate differentiated commercialization playbooks across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic variation in clinical practice, regulatory environments, and consumer preferences creates distinct regional dynamics that shape strategic priorities for market entrants and incumbents alike. In the Americas, established veterinary networks, high pet ownership rates, and strong consumer propensity to spend on preventative and advanced care make market access and clinical evidence the primary levers for differentiation. Meanwhile, supply chain considerations and reimbursement structures influence how manufacturers prioritize distribution and promotional investments across national and subnational markets.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse market maturity levels, creating opportunities for regionally tailored product registrations and differentiated channel strategies. Local clinical guidelines and antimicrobial stewardship programs in parts of this region can affect pharmaceutical utilization patterns, prompting manufacturers to emphasize stewardship-aligned messaging and diagnostic-enabled prescribing. Across the Asia-Pacific region, rapid pet ownership growth, expanding urban veterinary infrastructures, and rising disposable incomes are accelerating demand for premium nutrition, modern diagnostics, and accessible therapeutic options, while market entry strategies must account for varied regulatory landscapes and local manufacturing incentives.

Collectively, these regional insights point to the need for flexible commercialization frameworks that balance global clinical evidence generation with localized regulatory strategies, channel partnerships, and marketing approaches adapted to differing consumer behaviors and healthcare delivery models.

Strategic corporate priorities and competitive moves that combine clinical credibility, supply reliability, and channel sophistication to win in animal health

Competitive positioning in companion animal health is increasingly determined by the ability to combine scientific credibility with scalable commercial execution. Leading companies are prioritizing integrated portfolios that blend diagnostics, therapeutics, and nutritional solutions, supported by outcome data and clinician education programs. Strategic alliances and selective acquisitions are common approaches to broaden capability sets, access proprietary technologies, and accelerate entry into adjacent therapeutic or distribution segments.

Operational excellence in manufacturing and regulatory affairs remains critical, particularly for injectable biologics and advanced diagnostics that require stringent quality systems. Organizations that invest in supply chain visibility and digital forecasting tools gain advantages in inventory optimization and service continuity. On the commercial front, digital marketing, omnichannel sales enablement, and enhanced field force training support more effective engagement with veterinary practices and pet owners. Moreover, a growing emphasis on post-market evidence and real-world data collection strengthens clinical value propositions and supports payer or institutional procurement discussions.

In this competitive environment, nimble mid-sized firms can outmaneuver larger incumbents by focusing on niche therapeutic areas or by offering differentiated, clinician-facing diagnostic platforms. Conversely, large integrated players leverage scale to deliver global supply continuity and broad distribution, making partnerships with regional specialists an effective route to localized growth.

Actionable strategic moves for executives to strengthen evidence generation, supply resilience, and commercial differentiation across channels

Industry leaders should pursue a multi-pronged action agenda designed to secure clinical trust, optimize supply chains, and accelerate commercial adoption. First, prioritize the generation of robust clinical and real-world evidence that demonstrates measurable improvements in patient outcomes and owner satisfaction; this will strengthen relationships with veterinary opinion leaders and support premium positioning. Next, redesign sourcing strategies to reduce tariff and logistical exposure through supplier diversification, localized production where feasible, and inventory flexibility that preserves service levels during disruptions.

Simultaneously, invest in digital infrastructure that supports remote monitoring, telehealth integration, and omnichannel commerce, thereby capturing new engagement points and improving adherence. Commercial teams should develop channel-specific value propositions tailored to online retailers, specialty stores, pharmacies, and clinic partners, ensuring consistent messaging and streamlined fulfillment options. Additionally, embed antimicrobial stewardship and regulatory compliance into product strategies to mitigate reputational and regulatory risk while demonstrating clinical responsibility. Finally, explore partnerships and targeted M&A to acquire niche technologies or distribution reach, accelerating time to market for high-value innovations.

By implementing these recommendations, organizations can build resilient, evidence-driven portfolios that address clinical needs and changing owner expectations while safeguarding margin and access in an increasingly complex global environment.

Robust mixed-method research approach combining practitioner interviews, regulatory analysis, and scenario planning to validate commercial and clinical insights

The research underpinning this analysis draws on a blended methodology combining qualitative and quantitative evidence collection, rigorous secondary research, and expert validation. Primary inputs included structured interviews with practicing veterinarians, distribution executives, and product development leaders, providing perspective on clinical workflows, adoption barriers, and channel economics. Secondary research encompassed regulatory guidance, clinical literature, and industry trend analyses to contextualize interview findings and identify systemic drivers.

Analytical methods included cross-segmentation synthesis to evaluate how animal type, product typology, formulation, distribution channel, and therapeutic focus interact to influence adoption and commercial outcomes. Scenario planning and sensitivity analysis were applied to assess potential impacts of external shocks such as tariff adjustments and supply chain disruptions. All findings were triangulated with expert review panels to ensure interpretive rigor and practical relevance. Limitations of the study are acknowledged where data variability or rapidly evolving regulatory conditions may affect near-term applicability, and recommendations are provided with pathways for targeted validation through additional primary research or pilot programs.

This multi-method approach ensures the insights are grounded in clinical reality, commercially actionable, and adaptable to evolving market conditions.

Concluding synthesis that links clinical innovation, operational resilience, and evidence-driven commercialization as the pillars of long-term success in animal health

In summary, companion animal health is entering a period of strategic consolidation and innovation where clinical evidence, supply chain agility, and channel sophistication will determine winners. Diagnostic advancements and digital health capabilities are changing the tempo of care, enabling earlier intervention and creating opportunities for products and services that demonstrate clear outcome benefits. Nutrition and pharmaceutical portfolios that align formulation convenience with therapeutic effectiveness will capture increasing owner investment and clinician preference.

Tariff-related pressures and regional regulatory variation require proactive sourcing and market entry strategies to preserve access and margin. Companies that integrate robust evidence generation with adaptive manufacturing footprints and differentiated commercial models will be better positioned to navigate volatility and secure sustainable growth. Ultimately, the path to long-term success relies on translating clinical innovation into scalable, practitioner-validated solutions that meet evolving owner expectations while upholding standards of stewardship and safety.

Stakeholders who act now to align R&D priorities, operational capabilities, and market access strategies will create durable competitive advantage in a rapidly maturing market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increasing adoption of telehealth platforms for virtual veterinary consultations
• 5.2. Rising consumer demand for breed-specific and condition-targeted pet nutrition plans
• 5.3. Integration of wearable health trackers for real-time monitoring of pet vital signs and activity levels
• 5.4. Expansion of pet insurance plans covering preventive care and specialized veterinary treatments
• 5.5. Advancement and commercialization of monoclonal antibody therapies for chronic canine diseases
• 5.6. Surge in veterinary acceptance and adoption of CBD-based therapies for pet pain management
• 5.7. Rapid growth of online veterinary pharmacies and direct-to-consumer medication distribution channels
• 5.8. Development of digital behavioral health tools addressing separation anxiety and stress in pets
• 5.9. Emerging demand for sustainably sourced ingredients and eco-friendly packaging in pet food products
• 5.10. Strengthening One Health collaborations to integrate pet disease surveillance with human health data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Health Market, by Animal Type

• 8.1. Cat
• 8.2. Dog
• 8.3. Horse

9. Companion Animal Health Market, by Product Type

• 9.1. Diagnostics
  • 9.1.1. Imaging
  • 9.1.2. In Vitro Diagnostics
  • 9.1.3. Monitoring Devices
• 9.2. Nutrition
  • 9.2.1. Specialized Pet Food
  • 9.2.2. Supplements
• 9.3. Pharmaceuticals
  • 9.3.1. Anti-Inflammatories
  • 9.3.2. Antibiotics
  • 9.3.3. Endocrine Treatments
  • 9.3.4. Pain Management
  • 9.3.5. Parasiticides
• 9.4. Vaccines

10. Companion Animal Health Market, by Formulation

• 10.1. Injectable
• 10.2. Oral
• 10.3. Topical

11. Companion Animal Health Market, by Distribution Channel

• 11.1. Online Retail
• 11.2. Pet Specialty Stores
• 11.3. Pharmacies
• 11.4. Veterinary Clinics

12. Companion Animal Health Market, by Therapeutic Area

• 12.1. Cardiovascular
• 12.2. Dental
• 12.3. Dermatology
• 12.4. Endocrine
• 12.5. Orthopedic
• 12.6. Parasitology

13. Companion Animal Health Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Companion Animal Health Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Companion Animal Health Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Elanco Animal Health Incorporated
  • 16.3.2. Zoetis Inc.
  • 16.3.3. Merck & Co., Inc.
  • 16.3.4. Boehringer Ingelheim International GmbH
  • 16.3.5. IDEXX Laboratories, Inc.
  • 16.3.6. Ceva Sante Animale S.A.
  • 16.3.7. Vetoquinol S.A.
  • 16.3.8. Virbac S.A.
  • 16.3.9. Dechra Pharmaceuticals PLC
  • 16.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. COMPANION ANIMAL HEALTH MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. COMPANION ANIMAL HEALTH MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. COMPANION ANIMAL HEALTH MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
• TABLE 248. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 250. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 293. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 294. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 295. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 296. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 297. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 298. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 299. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 300. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 301. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
• TABLE 302. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
• TABLE 303. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 304. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 305. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 306. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 307. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 308. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 309. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 310. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 311. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 312. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 313. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 314. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 315. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018